Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1Breast 1

Conditions

Severe Combined Immunodeficiency 1Neuroblastoma 1Neoplasms 1Mucopolysaccharidosis I 1Hematologic Neoplasms 1

Interventions

Temozolomide 299Radiotherapy 219Bevacizumab 139Carboplatin 91Cyclophosphamide 88Etoposide 82Filgrastim 72Vincristine 69Irinotecan 69Magnetic Resonance Spectroscopy 64Cisplatin 59Radiation 58Radiosurgery 52Surgical Procedures, Operative 41Peripheral Blood Stem Cell Transplantation 40Topotecan 39Doxorubicin 39Lomustine 37Carmustine 36sargramostim 35Granulocyte Colony-Stimulating Factor 35Melphalan 34Nivolumab 32Chemotherapy, Adjuvant 32Radiotherapy, Intensity-Modulated 29Isotretinoin 29Everolimus 29Erlotinib Hydrochloride 27Thiotepa 25Vorinostat 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Prospective Studies × CNS × Clear all
NCT00695279 2024-10-30

Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products

St. Jude Children's Research Hospital

Completed
41 enrolled
CNSOther hematologic neoplasm

Mucopolysaccharidosis I, Neoplasms, Neuroblastoma, Severe Combined Immunodeficiency, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡